DUB targets explored
In the DUB field
Commercializing expert research into
Dubs and Ubiquitin pathway
Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.